Biotek-snakken — August 2024
-
Genovis Announces Strategic Divestment of Antibody Business to Leinco Technologies Inc.
Genovis Announces Strategic Divestment of Antibody Business to Leinco Technologies Inc.
Genovis, a leading innovator in enzyme technology, today announced the successful divestment of its
News Powered by Cision (news.cision.com)
-
Genovis AB: Half-Yearly Report January - June 2024
Half-Yearly Report January - June 2024
A stable quarter despite subdued market conditions April – June 2024 · Net sales totaled
News Powered by Cision (news.cision.com)
-
Egetis Therapeutics AB -New data shows tiratricol (Emcitate
) treatment in patients with MCT8 deficiency is associated with survival benefits (https://www.egetis.com/mfn_news/new-data-shows-tiratricol-emcitate-treatment-in-patients-with-mct8-deficiency-is-associated-with-survival-benefits/) -
Kan Egetis Therapeutics nå at gøre brug af den "Tranche B" finansering der udløber d. 30. sep. 2024 jf. Q1 2024 eller kunne de risikere en nyemission? https://storage.mfn.se/c5f505c7-a58b-48a3-bc29-596da4764331/q1-2024-report-eng-240502-final3.pdf
-
Genovis Q2 2024: Focusing fully on the enzyme business
"Consequently, our updated fair value range amounts to SEK24-102, with a base case of SEK52."
-
Vedr.; Infant Bacterial Therapeutics:
"The final patient participating in “The Connection Study” is expected to leave the study during July 2024. The results from the study are anticipated during Q3 2024" (April 4, 2024).
Dvs. at resultatet forventes senest den kommende måned.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind